enGene Therapeutics Inc News powered by B2i Technologies - SmartWire

enGene Announces Updated Interim Results From LEGEND Pivotal Cohort

Thu, 07 May 2026 07:00:00 EST

54% complete response (CR) rate at any time; 43% six month CR rate

Low rate of progression to muscle-invasive or higher disease (3.2%)

Low percentage of patients experienced treatment-related adverse events (TRAEs) (55%), nearly all of which were mild

Low percentage of patients experienced TRAEs leading to treatment interruption...

enGene Announces Name Change to enGene Therapeutics Inc.

Tue, 07 Apr 2026 08:00:00 EST

Name change reflects transition towards potential commercial organization in 2027
Planned Biologics License Application (BLA) submission for detalimogene in 2H 2026
BOSTON & MONTREAL - enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral...

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

Mon, 09 Mar 2026 06:00:00 EST

LEGEND pivotal cohort update planned for a spring 2026 medical conference
12-month complete response data from LEGEND pivotal cohort expected in 2H 2026
Biologics License Application (BLA) submission for detalimogene planned for 2H 2026
Cash and marketable securities of $312.5 million expected to provide cash runway into 2H...

enGene to Participate in Upcoming Investor Conferences

Fri, 20 Feb 2026 08:00:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN or "enGene"), a clinical-stage, non-viral genetic medicines company, today announced that management will participate in the following investor conferences:
Oppenheimer 36th Annual Healthcare Life Sciences Conference
Date: Thursday, February 26, 2026
Format: Presentation
Time: 1:20 p.m. ET
Leerink...

enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Wed, 04 Feb 2026 08:00:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN or "enGene"), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 2:30 p.m. ET.
A live webcast of the fireside chat can be accessed on the "Events and...

enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.

Tue, 20 Jan 2026 17:35:00 EST

Up to $100 million in additional loan proceeds provide additional financial flexibility to advance detalimogene development and commercialization for bladder cancer
$25 million advanced at close of the amendment to refinance existing debt facility
BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN, "enGene"...

enGene Reports Full Year 2025 Financial Results and Provides Business Update

Mon, 22 Dec 2025 16:03:00 EST

Completed enrollment in LEGEND's pivotal cohort with 125 patients in high-risk, BCG-unresponsive NMIBC with carcinoma in situ
Reported preliminary 6-month complete response rate (62%) in pivotal cohort patients enrolled under amended LEGEND protocol
enGene selected for FDA's CDRP Program to support CMC readiness
Biologic License...

enGene's Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness

Tue, 02 Dec 2025 07:30:00 EST

enGene one of nine companies awarded CDRP per year
Program aims to support CMC development of products with expedited clinical development timeframes and provide patients with earlier access to these products
Detalimogene has already been manufactured at commercial scale, and CDRP provides additional FDA CMC interactions ahead of a potential BLA submission in 2H...

enGene to Present at the Piper Sandler 37th Annual Healthcare Conference

Tue, 25 Nov 2025 07:30:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN or "enGene"), a clinical-stage, non-viral genetic medicines company, today announced that Alex Nichols, Ph.D., Chief Strategy and Operations Officer, will present at the Piper Sandler 37^th Annual Healthcare Conference on Tuesday, December 2, 2025, at 12:10 p.m. ET.
A webcast of the presentation can be accessed on the "Events and Presentations"...

enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants

Thu, 13 Nov 2025 00:27:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced the pricing of its previously announced underwritten public offering of 12,558,823 common shares at a public offering price of $8.50 per share and pre-funded warrants to purchase 2,735,295 shares of its common shares at an offering price of $8.4999 per pre-funded...

enGene Announces Proposed Public Offering of Common Shares

Wed, 12 Nov 2025 16:01:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced that it has commenced an underwritten public offering of its common shares. All common shares to be sold in the offering will be offered by enGene. In addition, enGene intends to grant the underwriters a 30-day option to purchase up to a number of additional common...

Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months

Tue, 11 Nov 2025 07:30:00 EST

Low rates of treatment-related adverse events (42%) and dose interruptions (1.6%)
Emerging detalimogene profile supports potential first line use in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer with CIS
LEGEND trial pivotal cohort completed enrollment with 125 patients, exceeding target
enGene to host...

enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial

Mon, 10 Nov 2025 16:05:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced that it will host a conference call and webcast tomorrow, November 11, 2025, at 8:00 a.m. ET to discuss new preliminary data from its pivotal cohort in the ongoing LEGEND trial of its novel, non-viral gene therapy candidate, detalimogene voraplasmid (also known as...

enGene to Participate in Upcoming Investor Conferences

Thu, 06 Nov 2025 18:00:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN or "enGene"), a clinical-stage, non-viral genetic medicines company, today announced that management will participate in the following investor conferences in November:
Guggenheim 2^nd Annual Healthcare Innovation Conference
Date: Tuesday, November 11, 2025
Time: 12:30 p.m. ET
Stifel 2025 Healthcare Conference

enGene Named a BioSpace 2026 Best Places to Work Winner

Tue, 04 Nov 2025 14:35:00 EST

enGene selected for its innovation in advancing non-viral genetic medicines and fostering a culture of collaboration and purpose
Selection follows BIOTECanada's 2025 Biotech Company of the Year award
BOSTON & MONTREAL - enGene Holdings Inc. ("enGene" or the "Company") (Nasdaq: ENGN), a clinical-stage, non-viral...

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Wed, 01 Oct 2025 16:03:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to four newly-hired employees, including Hussein Sweiti, M.D., MSc, Chief Medical Officer, with a grant date of September 30, 2025. The inducement award for Dr. Sweiti consists of a non-qualified stock option to purchase an...

enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer

Tue, 30 Sep 2025 07:30:00 EST

Bladder cancer development leader who helped drive recent FDA product approval in NMIBC joins to lead research and development strategy
Appointment strengthens enGene's clinical development and regulatory capabilities ahead of planned 2H 2026 BLA submission for detalimogene
BOSTON & MONTREAL - enGene Holdings...

enGene Reports Third Quarter 2025 Financial Results and Provides Business Update

Thu, 11 Sep 2025 16:03:00 EST

Achieved target enrollment milestone for LEGEND trial pivotal cohort in high-risk BCG unresponsive NMIBC with carcinoma in situ
LEGEND's pivotal cohort data update planned for 4Q 2025
Detalimogene granted Regenerative Medicine Advanced Therapy (RMAT) designation by FDA
Biologic License Application (BLA) submission planned for 2H...

enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort

Wed, 03 Sep 2025 07:30:00 EST

Target enrollment of 100 patients with high-risk, BCG-unresponsive NMIBC with CIS achieved
enGene plans to provide an update from LEGEND's pivotal cohort in 4Q 2025
Biologic License Application (BLA) submission planned for 2H 2026
BOSTON & MONTREAL - enGene Holdings Inc....

enGene to Participate in Upcoming Investor Conferences

Wed, 27 Aug 2025 08:00:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN or "enGene"), a clinical-stage, non-viral gene therapy company, today announced that management will participate in the following investor conferences in September:
2025 Wells Fargo Healthcare Conference
Date: Wednesday, September 3, 2025
Time: 8:45 a.m. ET
H.C. Wainwright 27^th Annual Global Investment...

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Mon, 04 Aug 2025 08:00:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral gene-based immunotherapy company, today reported the grant of inducement equity awards to three newly-hired employees, with a grant date of July 31, 2025. The inducement awards consist of non-qualified stock options to purchase an aggregate 93,200 of the Company's common shares. The options each have an...

enGene Announces Board and Leadership Appointments to Support Commercial Readiness

Tue, 08 Jul 2025 08:00:00 EST

Philip Astley-Sparke, William Grossman and Michael Heffernan join the Board
Management promotions strengthen clinical and regulatory operations
Matthew Boyd named Chief Regulatory Officer, Jill Buck Chief Development Officer, and Katherine Chan Executive Director, Urology Clinical Lead

FDA Grants RMAT Designation for enGene's Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

Wed, 25 Jun 2025 08:00:00 EST

Regenerative Medicine Advanced Therapy (RMAT) designation provides access to accelerated development tools
Designation recognizes the potential of detalimogene to address significant unmet need
BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN, or "enGene" or the "Company"), a clinical-stage, non-viral...

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Tue, 17 Jun 2025 08:00:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to four newly-hired employees, including Amy Pott, Chief Global Commercialization Officer, with a grant date of June 16, 2025. The inducement award for Ms. Pott consists of a non-qualified stock option to purchase an aggregate...

enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

Thu, 12 Jun 2025 08:00:00 EST

Additional preliminary data from ongoing LEGEND study of detalimogene in pivotal cohort of BCG-unresponsive NMIBC with CIS anticipated in 2H 2025
Biologics License Application (BLA) filing planned for mid-2026 remains on track
EMA Scientific Advice completed; Indicated data could be suitable for a Contingent Marketing Authorization Application

enGene Announces the Resignation of its Chief Medical Officer

Wed, 04 Jun 2025 08:30:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, announced today that Dr. Raj Pruthi resigned from his role as Chief Medical Officer on June 3, 2025. Dr. Pruthi's resignation as Chief Medical Officer will take effect on June 16, 2025. He will be supporting the organization to ensure an orderly transition of his responsibilities...

enGene to Present at the Jefferies Global Healthcare Conference

Thu, 29 May 2025 08:00:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference in New York City on Wednesday, June 4, 2025, at 11:05 a.m. ET.
A live webcast of the presentation can be accessed under the "Investors" section of the...

enGene Names Amy Pott as Chief Global Commercialization Officer

Wed, 28 May 2025 07:30:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced the appointment of Amy Pott as Chief Global Commercialization Officer. In this role, Ms. Pott will serve as the Company's first dedicated executive for commercialization planning and execution, reporting to enGene's Chief Executive Officer, Ron Cooper.

enGene to Participate in Upcoming Investor Conferences

Tue, 29 Apr 2025 07:30:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced that management will present at upcoming investor conferences in May 2025. Details of the conferences are below:
Conference: 2025 Bloom Burton & Co. Healthcare Investor Conference
Date: Monday, May 5, 2025
Time: 2:00...

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Fri, 04 Apr 2025 08:00:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to seven newly-hired employees, with a grant date of April 2, 2025. The inducement awards consist of a non-qualified stock options to purchase an aggregate 144,650 of the Company's common shares. The options each have an exercise...

enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum

Tue, 01 Apr 2025 08:00:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Executive Officer, will present at the Stifel 2025 Virtual Targeted Oncology Forum, on Tuesday, April 8, 2025, at 4:00 p.m. ET.
A live webcast of the presentation can be accessed under the "Investors" section of the enGene website at...

enGene Reports First Quarter 2025 Financial Results and Provides Business Update

Mon, 10 Mar 2025 15:05:00 EST

Additional preliminary data from ongoing LEGEND study of detalimogene in BCG-unresponsive NMIBC with CIS, including pivotal cohort, anticipated in 2H 2025
Biologics License Application (BLA) filing planned for mid-2026 remains on track
Cash and marketable securities of $272.8 million expected to provide runway into 2027

enGene to Participate in the Leerink Partners Global Healthcare Conference

Tue, 04 Mar 2025 08:00:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference, taking place in Miami, FL on Tuesday, March 11, 2025, at 1:00 p.m. ET.
A live webcast of the fireside chat can be accessed...

enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Tue, 04 Feb 2025 08:00:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in...

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Fri, 31 Jan 2025 16:05:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in...

enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)

Thu, 30 Jan 2025 08:00:00 EST

Detalimogene voraplasmid is a novel, investigational, pivotal-stage, non-viral genetic medicine designed to mitigate systemic risks and deliver durable efficacy for patients with high-risk NMIBC, including Bacillus Calmette-Guérin (BCG)-unresponsive disease
Ongoing, pivotal, registrational LEGEND study is actively enrolling patients with sites participating in the USA, Canada, Europe and the...

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Mon, 30 Dec 2024 16:05:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in...

enGene Reports Full Year 2024 Financial Results and Provides a Business Update

Thu, 19 Dec 2024 16:05:00 EST

BLA filing for detalimogene in BCG-unresponsive NMIBC with CIS on track for mid-2026
All cohorts of the Phase 2 LEGEND study now recruiting under updated protocol
Additional preliminary data from pivotal cohort anticipated in 2H 2025
Cash, cash equivalents and marketable securities of $297.9 million provide runway into...

enGene to Participate in Upcoming Investor Conferences

Mon, 25 Nov 2024 08:00:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in...

enGene to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Tue, 05 Nov 2024 09:00:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in...

enGene Announces $60 Million Private Placement Financing

Fri, 25 Oct 2024 08:00:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in...

enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Tue, 22 Oct 2024 16:05:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in...

enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer

Mon, 21 Oct 2024 08:45:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in...

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Tue, 01 Oct 2024 16:05:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in...

Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort

Thu, 26 Sep 2024 06:30:00 EST

Data from pivotal cohort demonstrate compelling clinical activity, consistent with Phase 1 results
Favorable tolerability profile with no drug-related discontinuations
Detalimogene's profile to date supports its potential as a foundational therapy for NMIBC
enGene to host a conference call to discuss preliminary data today at 8:00 a.m. ET

enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update

Tue, 10 Sep 2024 16:33:00 EST

Company remains on track to report preliminary LEGEND data in September 2024
Cash and cash equivalents of $257.7 million provide runway into 2027
BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN, or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead investigational...

enGene to Participate in Upcoming Investor Conferences

Wed, 28 Aug 2024 16:05:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program detalimogene voraplasmid (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today...

enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Wed, 24 Jul 2024 16:05:00 EST

BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC), today announced the grant of an inducement equity award to Ron Cooper, the Company's newly-appointed Chief Executive Officer.

enGene Announces Appointment of Ron Cooper as Chief Executive Officer

Wed, 24 Jul 2024 06:30:00 EST

Ron Cooper succeeds Jason Hanson as Chief Executive Officer and Director
Company also announces Dr. Raj Pruthi's promotion to Chief Medical Officer
BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead...

enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update

Fri, 14 Jun 2024 07:01:00 EST

Company announces plans for initial indication expansion for EG-70 into high-risk papillary-only NMIBC
BOSTON & MONTREAL - enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive high-risk...